Leflunomide as an alternative csDMARD for rheumatoid arthritis in a resource-constrained setting: A real-life experience
LEF has been demonstrated to be an effective alternative csDMARD for patients with inadequate response to MTX-based therapies, reducing the mean CDAI from 26 to 11. It adds a viable alternative for RA patients with poor prognostic factors and lack of access to bDMARDs.
Authors
- P E Mkhize
- Adie Viljoen (ORCID: https://orcid.org/0000-0002-3125-7998)
Institutions
- Stellenbosch University (ZA)
- Tygerberg Hospital (ZA)
Publication Details
- Journal
- South African Medical Journal
- Published
- 2025-05-02
- DOI
- https://doi.org/10.7196/samj.2025.v115i4.2536
- Citations
- 2
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.34
Funders
- Universiteit Stellenbosch